Tag: Ctcl

In clinical trials for advanced-stage cutaneous T-cell lymphoma (CTCL), bexarotene demonstrated an overall response rate of 45-55% in patients refractory to previous systemic therapies. Understanding **what is the mechanism of action of bexarotene** involves exploring its role as a selective retinoid X receptor (RXR) agonist and its profound influence on gene transcription.

First approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL), the medication known as **bexarotene** is a member of the retinoid drug family. However, it is a distinct subclass of retinoids, often called rexinoids, because it selectively targets retinoid X receptors (RXRs) rather than retinoic acid receptors (RARs).

According to the Cutaneous Lymphoma Foundation, bexarotene gel (brand name Targretin) is a topical retinoid approved for the treatment of early-stage cutaneous T-cell lymphoma (CTCL) in patients who have not responded to, or tolerated, other therapies. This specialized gel works directly on skin lesions to help manage the symptoms of this rare skin cancer.